Amber Dance is an award-winning freelance science writer and editor based in Southern California. She is a contributor at Knowable Magazine, program director for the New Horizons in Science briefings at the ScienceWriters annual conference for the Council for the Advancement of Science Writing, and a science writing instructor UCLA Extension. She is also a Fictionary StoryCoach Certified Editor.
Amber Dance
Science writer and editor
From this contributor
Levels of autism severity in diagnostic manual track with intelligence
A rating of high severity of autism from the DSM-5, the latest version of the “Diagnostic and Statistical Manual of Mental Disorders,” tracks with low intelligence scores.
Levels of autism severity in diagnostic manual track with intelligence
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.